Compare NetFlix Inc (NFLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Sanofi SA — how do they compare? NetFlix Inc trades at $76.25 (market cap $316.58B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: NetFlix Inc is far larger — about 3.1× Sanofi SA's market cap, and Sanofi SA pays a 5.65% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | SNY | |
|---|---|---|
Market Cap | $316.58B | $103.41B |
Sector | Consumer Cyclical | Health |
52-Week High | $124.77 | $52.34 |
52-Week Low | $67.60 | $41.33 |
Enterprise Value | $321.77B | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $76.03, down 2.84% on the day, amid a bearish technical signal and recent price weakness. The stock is near its 52-week low, with support at $76 and resistance at $78. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $45.18 billion and net income of $10.98 billion, and has beaten EPS estimates for the last three quarters. Analyst sentiment remains largely positive with a consensus buy rating and price target of $88.95, though recent news highlights concerns over the stock's performance streak.
The outlook for NFLX is mixed; strong fundamentals and analyst optimism suggest potential upside, but technical bearishness and competitive pressures pose risks. Investors should weigh robust profitability and ad-tier expansion against market volatility and execution challenges in the streaming sector.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
